Drug intelligence / Profile preview

AP-001

Development stage: Preclinical
Lead developer: BetterLife Pharma
Modality: Recombinant Proteins and Enzymes
Administration: Topical

Overview

AP-001 is a topical formulation of interferon α2b, initially developed by Altum Pharmaceuticals and subsequently acquired by BetterLife Pharma. It is being developed as a potential treatment for Human Papillomavirus (HPV). Interferon α2b is a recombinant cytokine known for its antiviral, antiproliferative, and immunomodulatory effects, which are mediated through binding to specific cell surface receptors and initiating a cascade of gene expression to combat viral infections.

Targets

IFNAR (Immune system modulation via type I interferon receptor)

Beyond the preview

Go deeper on AP-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AP-001.

Explore the full profile